TCG Crossover Management
TCG Crossover Management reported 54 stocks worth $4.2B in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are ABVX (19.2%), TNGX (6.8%) and CGON (6.3%). Compared with Q1 2026, the fund opened new positions in ZLAB, AURA and TRAX, added to AVTX and MNPR, trimmed ABVX, TNGX and COGT and sold out of FULC, LQDA and URGN.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  ABVX Abivax SA | $801M | 19.2% | 6M | −473K (−7%) | 8 of 8 | |
| 2 |  TNGX Tango Therapeutics Inc | $284M | 6.8% | 9.1M | −1.4M (−14%) | 7 of 8 | |
| 3 |  CGON CG Oncology Inc | $261M | 6.3% | 3.7M | No change | 8 of 8 | |
| 4 |  COGT Cogent Biosciences Inc | $188M | 4.5% | 4.9M | −92K (−2%) | 8 of 8 | |
| 5 |  IMVT Immunovant Inc | $172M | 4.1% | 4.5M | No change | 3 of 8 | |
| 6 |  SYRE Spyre Therapeutics Inc | $169M | 4.1% | 1.9M | No change | 4 of 8 | |
| 7 |  DNTH Dianthus Therapeutics Inc | $163M | 3.9% | 1.7M | No change | 7 of 8 | |
| 8 |  MIRM Mirum Pharmaceuticals Inc | $124M | 3.0% | 1.1M | No change | 3 of 8 | |
| 9 |  ZLAB Zai Lab Ltd | $117M | 2.8% | 6.1M | New position | 1 of 8 | |
| 10 |  AMLX Amylyx Pharmaceuticals Inc | $112M | 2.7% | 6.2M | No change | 8 of 8 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
CENTESSA PHARMACEUTICALS PLC | $170M | 4.3M |
 FULC Fulcrum Therapeutics Inc | $40.3M | 5.3M |
 LQDA Liquidia Corporation | $15.2M | 403K |
 URGN Urogen Pharma Ltd | $7.3M | 405K |
 GPCR Structure Therapeutics Inc | $6.8M | 140K |
🔒 Free account: see all 7.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 14, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →TCG Crossover Management 13F FAQ
What does TCG Crossover Management own?
TCG Crossover Management reported 54 stocks worth $4.2B in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are ABVX (19.2%), TNGX (6.8%) and CGON (6.3%). The table above lists every position in the filing (the top 10 without an account).
What did TCG Crossover Management buy and sell in Q2 2026?
Compared with Q1 2026: 12 new positions, 2 added to, 9 trimmed and 7 sold out. New positions include ZLAB, AURA and TRAX. It sold all of FULC, LQDA and URGN.
When will TCG Crossover Management file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is TCG Crossover Management's portfolio worth?
The Q2 2026 filing reports $4.2B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.